---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-25-080248"
form_type: "8-K"
ticker: "CLDX"
cik: "0000744218"
company_name: "Celldex Therapeutics, Inc."
filed_at: "2025-08-19T23:59:59+00:00"
generated_at: "2026-05-17T11:38:38.724543+00:00"
event_type: "other_material"
sentiment: "negative"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Celldex Phase 2 barzolvolimab in EoE meets primary endpoint but no clinical benefit; advancement stopped

## Summary
- Primary endpoint met: peak mast cell count reduced by -36.0 vs placebo -2.7 (p<0.0001) at Week 12.
- No improvement in Dysphagia Symptom Questionnaire (DSQ) (p=0.33) or endoscopic EREFS score (p=0.95).
- Company will not advance barzolvolimab in EoE; safety profile favorable at 300 mg Q4W.
- Pipeline continues in chronic spontaneous urticaria, atopic dermatitis, prurigo nodularis, and inducible urticaria.
- Full study (28-week treatment, 44-week total) outcomes consistent with 12-week results.

## SEC filing metadata
- accession: 0001104659-25-080248
- form_type: 8-K
- ticker: CLDX
- cik: 0000744218
- company_name: Celldex Therapeutics, Inc.
- filed_at: 2025-08-19T23:59:59+00:00
- event_type: other_material
- sentiment: negative
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/744218/000110465925080248/0001104659-25-080248-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/744218/000110465925080248/tm2523903d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-25-080248
- JSON: https://secwatch.observer/filing/0001104659-25-080248.json
- Plain text: https://secwatch.observer/filing/0001104659-25-080248.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.